Search Results - therapeutics+%3e+oncology

137 Results

Sort By:

Engineered Gamma Delta T-Cells and Methods of Making and Using Thereof (UCLA Case No. 2020-913)

UCLA researchers in the Department of Molecular Immunology & Molecular Genetics have developed gamma delta (gd) T cell receptor gene-modified immune cells derived from stem and progenitor cells that enable scalable, off-the-shelf allogeneic cell therapies with broad therapeutic potential. BACKGROUND: Cell-based immunotherapies have demonstrated...

Published: 3/4/2026 | Inventor(s): Lili Yang, Derek Lee, Tyler Halladay

Keywords(s):

Category(s): Diagnostic Markers > Immunology, Diagnostic Markers > Cancer, Life Science Research Tools > Cell Lines, Therapeutics > Oncology, Therapeutics > CNS and Neurology, Therapeutics > Hematology, Therapeutics > Autoimmune, Therapeutics > Gene Therapy And Editing, Therapeutics > Stem Cells And Regenerative Medicine, Therapeutics > Infectious Diseases

Microbial Regulation of Immune Tolerance and Risk for Cancer (UCLA Case No. 2026-153)

Details available soon. Please contact UCLA Technology Development Group if you have any questions or would like more information in the meantime.

Published: 3/4/2026 | Inventor(s): Elaine Hsiao

Keywords(s):

Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy

Transient Transcription Factor Reprogramming to Rejuvenate Exhausted Tumor-Specific T Cells Into Stem-Like Memory T Cells (UCLA Case No. 2024-240)

Details available soon. Please contact UCLA Technology Development Group if you have any questions or would like more information in the meantime.

Published: 3/9/2026 | Inventor(s): Tyler McCaw

Keywords(s):

Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy

Compositions and Methods to Modulate MAVS-Mediated Immunity (UCLA Case No. 2026-096)

UCLA researchers in the Department of Microbiology, Immunology, and Molecular Genetics have developed methods to target TOM70, a mitochondrial outer membrane protein, to selectively modulate innate immune signaling and control pathological or protective immune responses across a range of clinical conditions. BACKGROUND: Innate immune detection of viral...

Published: 2/18/2026 | Inventor(s): Lena Pernas

Keywords(s):

Category(s): Diagnostic Markers > Targets And Assays, Diagnostic Markers > Immunology, Diagnostic Markers > Cancer, Platforms > Diagnostic Platform Technologies, Therapeutics > Oncology, Therapeutics > Infectious Diseases, Therapeutics > Immunology And Immunotherapy, Therapeutics > Inflammation And Inflammatory Diseases, Therapeutics > Autoimmune, Therapeutics > Vaccines

The Use of Voltage Sensitive Mitochondrial Uncouplers as Selective Anti-Cancer Drugs (UCLA Case No. 2022-327)

UCLA researchers from the Department of Medicine have identified an anti-cancer drug that targets mitochondrial membrane potential to selectively kill tumor cells, showing efficacy for traditionally treatment-resistant lung cancers. BACKGROUND: Non-small cell lung cancer (NSCLC) is a devastating disease that will claim the lives of approximately 125,000...

Published: 2/17/2026 | Inventor(s): David Shackelford

Keywords(s):

Category(s): Therapeutics > Respiratory And Pulmonary, Therapeutics > Oncology

Regulated Gene Expression During Differentiation of Mature T Cells (UCLA Case No. 2022-147)

UCLA researchers from the Department of Pathology & Laboratory Medicine have developed a process to genetically modify stem cells to express transgenes in a regulated, stage-specific manner, avoiding the negative consequences of transgene expression during T cell development. Contact UCLA Technology Development Group for more information.

Published: 1/27/2026 | Inventor(s): Gay Crooks, Donald Kohn

Keywords(s):

Category(s): Therapeutics > Gene Therapy And Editing, Therapeutics > Stem Cells And Regenerative Medicine, Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy, Therapeutics > Inflammation And Inflammatory Diseases

Enhancing T Cell Production in Vitro From Stem and Progenitor Cells (UCLA Case No. 2022-257)

UCLA researchers from the Department of Pathology and Laboratory Medicine have developed an innovative differentiation method to increase T cell production for T cell immunotherapy. Contact UCLA Technology Development Group for more information.

Published: 1/27/2026 | Inventor(s): Gay Crooks, Christopher Seet

Keywords(s):

Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy

Peri-Operative Cancer Therapy to Preserve Anti-Tumor Immune Surveillance (UCLA Case No. 2025-257)

UCLA Researchers from the Department of Surgery have developed a novel approach to preserve anti-tumor immunity in the peri-operative period through modulation of clinically relevant molecular and cellular targets. BACKGROUND: Surgical resection with curative intent is a mainstay of treatment for many solid tumors. However, even when the tumor is macroscopically...

Published: 2/4/2026 | Inventor(s): Tyler McCaw, Joseph Crompton

Keywords(s):

Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy

Generation of Therapeutic Human Anti-Trop-2 Extracellular Domain Antibodies (UCLA Case No. 2026-026)

UCLA researchers from the Department of Molecular and Medical Pharmacology and the Department of Microbiology, Immunology and Molecular Genetics have developed a panel of human antibodies and chimeric antigen receptors targeting Trop-2, providing diagnostic and therapeutic resources for targeting Trop2-driven cancer. BACKGROUND: Trophoblast cell surface...

Published: 12/23/2025 | Inventor(s): Tanya Stoyanova, Owen Witte

Keywords(s):

Category(s): Diagnostic Markers > Cancer, Diagnostic Markers > Targets And Assays, Life Science Research Tools > Antibodies, Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy

Combinatorial RNA-LNP Immunotherapy for Enhanced Pattern Recognition Receptor (PRR) Engagement, Targeted Dendritic Cell (DC) Activation, and Versatile (UCLA Case No. 2025-237)

UCLA researchers in the Department of Molecular and Medical Pharmacology have developed a cancer immunotherapy platform that uses lipid nanoparticle (LNP) delivery of modified RNA constructs to activate dendritic cells, enhance CD8+ T-cell priming, and drive potent anti-tumor immunity. BACKGROUND: Effective cancer immunotherapy requires robust activation...

Published: 12/23/2025 | Inventor(s): Caius Radu

Keywords(s):

Category(s): Therapeutics > Oncology, Therapeutics > Vaccines, Therapeutics > Infectious Diseases

1 2 3 4 5 6 7 8 9 10 ...